Morphic Holding, Inc. (31Y.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
At close: 03:29PM CEST
| Previous close | 25.40 |
| Open | 25.60 |
| Bid | 25.80 x N/A |
| Ask | 26.60 x N/A |
| Day's range | 25.60 - 25.60 |
| 52-week range | 18.50 - 56.50 |
| Volume | |
| Avg. volume | 3 |
| Market cap | 1.319B |
| Beta (5Y monthly) | 1.42 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.37 |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 100.50 |
- GuruFocus.com
Morphic Holding Inc (MORF) Q1 2024 Earnings: A Detailed Review
Insights into Financial Performance and Strategic Developments
GlobeNewswireMorphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
- Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Appointed Dr. Simon Cooper as Chief Medical Officer- -Anticipate dosing first patient in GARNET Phase 2 study of MORF-057 in patients with moderate-to-severe Crohn’s disease in second quarter- -Ended first quarter with $658.8 million in cash, cash equivalents, and marketable securities; cash runway into second half of 2027- WALTHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasda
ZacksWhat Makes Morphic (MORF) a New Buy Stock
Morphic (MORF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
© 2024 Yahoo. All rights reserved.